Reprogramming chemoimmunotherapy via biomimetic cell membrane- clay platform to amplify prime-boost antitumor...

Area of Science:

• Biomaterials Science
• Cancer Immunology
• Nanotechnology

Background:

• Chemoimmunotherapy combines chemotherapy and immunotherapy for cancer treatment.
• Conventional strategies often precede immunotherapy with chemotherapy, leading to reduced immune response.
• The timing of immune activation and cytotoxic treatment critically impacts therapeutic efficacy.

Purpose of the Study:

• To develop an immune-priming chemoimmunotherapy strategy using cancer cell membrane-coated layered double hydroxide biomaterials (CCM-LDHs).
• To investigate the therapeutic efficacy of immunotherapy preceding trimodal photochemotherapy.
• To compare the novel strategy with conventional chemoimmunotherapy sequences.

Main Methods:

• Fabrication of cancer cell membrane-coated layered double hydroxide biomaterials (CCM-LDHs).
• Utilized BSA coated CpG-associated LDHs as an immunomodulatory adjuvant.
• Administered immunotherapy prior to trimodal photochemotherapy in *in vitro* and *in vivo* models.

Main Results:

• CCM-LDHs functioned as antigen reservoirs and homologous tumor-targeting agents.
• The immune-priming strategy significantly enhanced cytotoxic T-cell responses.
• Established robust immunological memory compared to conventional chemoimmunotherapy.

Conclusions:

• Immune-priming chemoimmunotherapy, using CCM-LDHs, offers superior anti-tumor immunity.
• This approach overcomes limitations of conventional chemoimmunotherapy by optimizing treatment sequence.
• Supports long-term anti-tumor immune surveillance and provides a promising cancer treatment strategy.